Jefferies Financial Group Inc. Takes $76.27 Million Position in Roivant Sciences Ltd. $ROIV

Jefferies Financial Group Inc. bought a new stake in Roivant Sciences Ltd. (NASDAQ:ROIV) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor bought 3,514,833 shares of the company’s stock, valued at approximately $76,272,000. Roivant Sciences accounts for approximately 0.4% of Jefferies Financial Group Inc.’s investment portfolio, making the stock its 26th largest position.

A number of other large investors also recently made changes to their positions in ROIV. Goldman Sachs Group Inc. increased its holdings in shares of Roivant Sciences by 15.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 2,433,386 shares of the company’s stock valued at $24,553,000 after purchasing an additional 324,764 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in shares of Roivant Sciences by 1.4% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 2,445,807 shares of the company’s stock valued at $24,678,000 after purchasing an additional 34,341 shares during the period. American Century Companies Inc. increased its holdings in shares of Roivant Sciences by 1.9% in the 2nd quarter. American Century Companies Inc. now owns 89,625 shares of the company’s stock valued at $1,010,000 after purchasing an additional 1,689 shares during the period. Russell Investments Group Ltd. increased its holdings in Roivant Sciences by 149.9% in the second quarter. Russell Investments Group Ltd. now owns 11,467 shares of the company’s stock worth $129,000 after buying an additional 6,879 shares during the last quarter. Finally, M&T Bank Corp increased its holdings in Roivant Sciences by 10.2% in the second quarter. M&T Bank Corp now owns 12,802 shares of the company’s stock worth $144,000 after buying an additional 1,181 shares during the last quarter. Institutional investors and hedge funds own 64.76% of the company’s stock.

Insider Activity at Roivant Sciences

In other Roivant Sciences news, CAO Jennifer Humes sold 13,538 shares of the stock in a transaction that occurred on Wednesday, April 8th. The stock was sold at an average price of $28.37, for a total transaction of $384,073.06. Following the transaction, the chief accounting officer owned 84,191 shares in the company, valued at $2,388,498.67. This trade represents a 13.85% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Frank Torti sold 587,390 shares of the stock in a transaction that occurred on Monday, February 23rd. The shares were sold at an average price of $27.51, for a total value of $16,159,098.90. Following the transaction, the insider owned 13,736,547 shares in the company, valued at approximately $377,892,407.97. This trade represents a 4.10% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last 90 days, insiders have sold 1,532,563 shares of company stock valued at $43,813,555. 10.80% of the stock is owned by company insiders.

Roivant Sciences Stock Down 3.0%

Shares of ROIV stock opened at $29.96 on Friday. Roivant Sciences Ltd. has a 12 month low of $10.59 and a 12 month high of $32.79. The business’s 50 day moving average is $28.46 and its two-hundred day moving average is $25.06. The company has a market cap of $21.44 billion, a PE ratio of -49.93 and a beta of 1.14.

Roivant Sciences (NASDAQ:ROIV) last announced its quarterly earnings results on Wednesday, May 20th. The company reported $0.28 EPS for the quarter, beating the consensus estimate of ($0.29) by $0.57. Roivant Sciences had a negative return on equity of 20.54% and a negative net margin of 3,629.19%.The company had revenue of $2.52 million for the quarter, compared to the consensus estimate of $3.41 million. During the same quarter last year, the company posted ($0.29) earnings per share. As a group, equities analysts expect that Roivant Sciences Ltd. will post -1.06 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

ROIV has been the topic of a number of research reports. Weiss Ratings restated a “sell (d)” rating on shares of Roivant Sciences in a report on Friday, May 8th. Sanford C. Bernstein initiated coverage on Roivant Sciences in a report on Friday, March 20th. They issued an “outperform” rating and a $35.00 price objective on the stock. TD Cowen increased their price objective on Roivant Sciences from $38.00 to $41.00 and gave the stock a “buy” rating in a report on Thursday. Piper Sandler restated an “overweight” rating on shares of Roivant Sciences in a report on Thursday. Finally, Leerink Partners set a $42.00 price objective on Roivant Sciences in a report on Thursday. Ten equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $33.05.

Roivant Sciences Profile

Roivant Sciences is a biopharmaceutical company focused on the development and commercialization of innovative therapies through a network of subsidiary businesses known as “Vants.” Founded in 2014, Roivant acquires or in-licenses clinical-stage assets that have progressed beyond proof of concept and seeks to advance them efficiently toward regulatory approval. By organizing each program into a dedicated subsidiary, the company aims to streamline decision-making, allocate resources more effectively, and accelerate development timelines.

The core activities of Roivant involve identifying promising drug candidates across a range of therapeutic areas, including neurology, rare diseases, immunology, oncology, and women’s health.